Milrinone Zentiva (Milrinone)

Milrinone is used in cardiovascular emergencies where enhanced cardiac contractility and vasodilation are needed.

• Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion.
• Cardiogenic shock: supports systemic circulation while other therapies are initiated.
• Post‑cardiac surgery low cardiac output syndrome: helps restore adequate perfusion during the early postoperative period.

• Milrinone selectively inhibits phosphodiesterase‑3 enzymes in cardiac and vascular smooth muscle cells, leading to accumulation of intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP enhances calcium influx during systole, producing a positive inotropic effect, while simultaneously promoting vasodilation through reduced calcium‑mediated smooth‑muscle contraction.

Milrinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea or vomiting: gastrointestinal discomfort.
• Arrhythmias: premature ventricular contractions or tachycardia.
• Hypotension: transient drop in blood pressure.
• Flushing: warmth and redness of skin.
• Thrombocytopenia: reduced platelet count.

Serious or Rare Side Effects

• Sustained ventricular tachyarrhythmias: potentially life‑threatening.
• Severe hypotension: may require vasopressor support.
• Myocardial ischemia: chest pain or ECG changes.
• Allergic reactions: rash, urticaria, or anaphylaxis.
• Liver enzyme elevation: abnormal hepatic function tests.

Milrinone requires careful monitoring and specific safety measures before and during therapy.

• Cardiac monitoring: continuous ECG and hemodynamic assessment.
• Electrolyte balance: correct potassium and magnesium levels to reduce arrhythmia risk.
• Renal function: adjust infusion rates in severe renal impairment.
• Concomitant vasodilators: avoid excessive hypotension when combined with other vasodilators.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations.
• Concurrent use of other phosphodiesterase inhibitors: risk of profound hypotension.
• High‑dose beta‑agonists: additive tachyarrhythmic potential.

Moderate Interactions (Monitor Closely)

• Diuretics: may exacerbate electrolyte disturbances.
• Anticoagulants: monitor for bleeding if thrombocytopenia occurs.
• Nitrates: monitor blood pressure for additive vasodilatory effect.